{"id":"NCT05174416","sponsor":"LianBio LLC","briefTitle":"A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM","officialTitle":"A Phase III, Randomized, Double-blinded, Placebo-controlled Clinical Study With A Long-term Extension to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-01-04","primaryCompletion":"2023-03-06","completion":"2024-07-22","firstPosted":"2021-12-30","resultsPosted":"2024-09-19","lastUpdate":"2024-09-19"},"enrollment":81,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Obstructive Hypertrophic Cardiomyopathy"],"interventions":[{"type":"DRUG","name":"Mavacamten","otherNames":["MYK-461","BMS-986327"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Mavacamten","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Mavacamtenis a novel, small molecule, selective allosteric inhibitor of cardiac-specific myosin, for the treatment of patients with symptomatic oHCM. This study will assess the efficacy and safety of mavacamten in Chinese adults with symptomatic oHCM.","primaryOutcome":{"measure":"Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient","timeFrame":"30 weeks","effectByArm":[{"arm":"Mavacamten","deltaMin":-51.05,"sd":6.15},{"arm":"Placebo","deltaMin":19.23,"sd":8.535}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":18},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["40632050","40299193","37639259","37336533"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["COVID-19","Upper respiratory tract infection","Hyperuricemia","Dizziness","Defect conduction intraventricular"]}}